At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,050 enrolled
Drug / intervention
sitagliptin phosphate +1 moredrug
Likely dose
sitagliptin phosphate 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
In Brief
A Phase 3 clinical trial evaluating sitagliptin phosphate and Comparator: metformin hydrochloride for Type 2 Diabetes Mellitus. Completed, enrolled 1,050 participants.
Detailed Summary
A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMar 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedMar 21, 2007
Enrollment StartMar 1, 2007
Primary CompletionJul 25, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.3 years ago
Interventions
sitagliptin phosphatedrug
(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
Comparator: metformin hydrochloridedrug
(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.